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Laboratory Notes From Behavioral Pharmacologists and 
Trainees: Considerations for the Discipline
Rick A. Bevins☒, Scott T. Barrett, Brady M. Thompson, and Steven T. Pittenger
University of Nebraska-Lincoln
Abstract
In several laboratory meetings, we discussed the challenges that face trainees in behavioral 
pharmacology. Major concerns, such as a difficult funding climate and limited academic job 
prospects were discussed at first. However, we decided to concentrate on ways to meet these 
challenges; versus focusing on negatives and listing gripes. Within this more constructive 
framework, we identified the importance of broadening training to aligned areas to enhance the 
capacity of behavioral pharmacologists to collaborate in multidisciplinary teams. With increased 
breadth of training comes the concern for a balance that does not cheat trainees out of the depth of 
training also needed for success. We believe that behavioral pharmacologists trained in this 
manner will be ideally positioned to be leaders of these translational research teams. Related to the 
breadth and depth of training is the recent concerns over replicability and reproducibility of 
published research. Behavioral pharmacologists, with the rigors of training in behavioral analysis 
and experimental design, can be at the forefront of this conversation. This will be especially true if 
current training is reinforced with additional experience in the use of cutting-edge statistical tools 
that address the complex experimental designs and large data sets that emerge from modern 
multidisciplinary collaborations. Finally, communicating the import and potential societal impact 
of our research to legislators, other scientists, educators, school children, neighbors, and 
acquaintances is needed to ensure that our field thrives. In closing, the process of explicitly 
discussing the challenges and potential solutions with current trainees will enhance their 
mentoring and training.
Evolving Conversations
The request from Dr. Alan Poling for contributions to this special section asked for 
reflections on “the defining features of behavioral pharmacology, its current status, and its 
probable future, including if possible consideration of areas where growth is possible.” I 
(Bevins) brought this suggestion to my laboratory crew and this sparked a thoughtful series 
of evolving conversations on a range of topics. The first conversation or two occurred at the 
closure of a laboratory meeting with 10 or 15 minutes left. Interestingly, in this brief time, 
the tone of the topics went quite negative. For example, and perhaps not surprising, one topic 
that recurred was the continuing poor budget outlook for the National Institutes of Health 
(NIH). What does this budget situation mean for early career investigators trying to establish 
☒Address correspondence to: Rick A. Bevins, Ph.D., Department of Psychology, University of Nebraska-Lincoln, 238 Burnett Hall, 
Lincoln, NE 68588-0308, 402-472-3721, rbevins1@unl.edu. 
HHS Public Access
Author manuscript
Behav Anal (Wash D C). Author manuscript; available in PMC 2016 December 08.
Published in final edited form as:
Behav Anal (Wash D C). 2016 November ; 16(4): 210–214. doi:10.1037/bar0000034.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
independent programs of research? Will this funding environment be cyclic or is this a new 
normal? If the latter, what does this mean for current and future trainees. Does the limited or 
lack of a science education received by most of our legislature, and the public in general, 
contribute to this situation? Perhaps related, there seems to be a dwindling number of job 
prospects, relative to the number of behavioral pharmacologists currently being trained. 
Although there are notable strongholds for academically-oriented behavioral 
pharmacologists within certain universities and medical centers, more often than not, our 
impression was that these positions were lost or reallocated to fields of neuroscience with a 
more molecular focus and often with little to no consideration of behavioral processes.
Rather than 15 minutes of a laboratory meeting here and 10 minutes there, we eventually 
decided to sit down and dedicate several lengthy discussions to this topic. We also decided to 
avoid negativity and frame the conversation in a more positive and constructive light. For 
example, instead of complaining about the reallocation of jobs, we should talk about how we 
compete successfully for those jobs, while maintaining our core identity as a behavioral 
pharmacologists. Similarly, how can we position ourselves to be more successful at 
competing for the limited grant dollars from NIH or other extramural funding agencies? The 
narrative that follows reflects a winnowed version of these conversations1.
Laboratory Notes
Breadth of training
By definition, behavioral pharmacology, since its inception, has been a multidisciplinary 
field. Today, the study of the effects of drugs on the brain and behavior can include such 
disciplines as psychology, pharmacology, neuroscience, chemistry, genetics, economics, 
evolutionary biology, sociology, computer science, and biomedical engineering. As the field 
of behavioral pharmacology moves forward, and as our understanding of the varied 
mechanisms of behavior expands, the need for individual researchers to become better 
versed in a wide range of theoretical and methodological approaches also expands. To meet 
these challenges and to remain competitive, the training for future (and current) behavioral 
pharmacologists ought to increase the breadth of topics to which trainees are exposed. Such 
training may equip individuals with the skills increasingly requisite for reviewing and 
conducting rigorous and informative science. Indeed, investigators who are versed in a wider 
array of applicable topics may be better positioned to help tackle complex scientific 
questions traditionally, and perhaps not traditionally, in the purview of behavior 
pharmacology. Such researchers are a boon on grant review panels, and as members of a 
research team. They are able to integrate a wider array of pertinent knowledge from an 
expanse of disciplinary approaches to ensure that our field continues to conduct science with 
the highest rigor, innovation, and application.
1To better understand the conversation, we thought it would be helpful if the reader knew where each author was in their training. Rick 
Bevins, as the PI of the Behavioral Neuropharmacology Laboratory (BNL), published his first behavioral pharmacology paper in 
1994. He has been on the faculty at the University of Nebraska-Lincoln (UNL) since 1996. Scott Barrett received his Bachelor’s 
degree at Utah State University working in the laboratory of Dr. Amy Odum. He completed his Ph.D. in 2015 at UNL and is now a 
post-doctoral scholar in the laboratory. Steven Pittenger received his Bachelor’s degree at Kansas State University working in the 
laboratory of Dr. Mary Cain. He is finishing his dissertation and will be starting a post-doctoral position with Dr. Marina Picciotto at 
Yale in August 2016. Brady Thompson finished his Bachelor’s degree at Nebraska Wesleyan University last year and is now a 
technician and manager in the BNL and an incoming graduate student.
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Depth versus breadth
With the need to expand training in an increasingly broad range of research fields also 
comes a need to ensure and to protect depth of training. Herein lies the challenge for 
trainees, mentors, and graduate programs: ensuring an increased breadth of training, while 
simultaneously maintaining quality and depth of training that has been the hallmark of 
behavior pharmacology. Meeting this challenge will not be easy and it will require constant 
vigilance to avoid training that produces behavioral pharmacologists that are “jack-of-all-
trades, masters-of-none.” On the other end of the continuum, we must avoid such narrow 
training that the individual is trapped in the ivory tower of the academy and unable to work 
on a research team addressing pressing scientific questions outside the comfortable 
boundaries of traditional training. If the balance is struck and we are successful, then the 
field of behavioral pharmacology will thrive. Indeed, to the extent that research in the field 
increasingly employs multidisciplinary approaches to a host of important societal issues, 
then institutional research teams, grant review committees, and editorial boards require 
individuals who are well-versed in a wide arrange of topics, but also highly knowledgeable 
in the area of their specialty.
Research teams
The idea that an individual could achieve expert status across all fields potentially interested 
in the discoveries of behavioral pharmacology research is by most standards, an 
unreasonable, if not impossible, expectation. This fact alone calls for a cohesive plan by 
experts to collaborate in a meaningful manner to solve complex societal questions. We have 
referred to scientific teams several times in these notes. However, to address the most 
complex and vexing problems facing society today will require an approach where scientific 
questions and answers move seamlessly across the disciplines and are addressed at each 
level in a manner communicable, useful, and informative to the other levels. For many 
health-related questions (e.g., drug abuse, obesity, schizophrenia, etc.), a behavioral 
pharmacologist trained in the manner we have been discussing would likely serve as a 
linchpin team member. Take as an example substance abuse with its estimated societal cost 
of $600 billion dollars a year (NIH, 2013). A behavioral pharmacologist could be ideally 
positioned to gather researchers that span public policy, intervention and prevention 
development, community-based participatory research, neuroimaging, behavioral 
pharmacology, neurobiology, genetic, and medicinal chemistry to answer an integrated set of 
questions central to the etiology of substance abuse. This approach is not novel per se, as 
there are a number of centers and program projects of this nature funded by the National 
Institute on Drug Abuse (NIDA). However, what we are suggesting is that behavioral 
pharmacologists seek training that will place them as leaders of such efforts.
Replication and reproducibility
Trainees in the field will continue to require rigorous instruction in the scientific method and 
hypothesis testing to ensure that future research in behavioral pharmacology persists as 
innovative, illuminating, and informative. Recently reported issues regarding scientific rigor 
and reproducibility highlight the need for current and future researchers to be trained in 
sound scientific design and state-of-the-art analytical approaches (Prinz et al., 2011; 
Bevins et al. Page 3
Behav Anal (Wash D C). Author manuscript; available in PMC 2016 December 08.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
"Trouble at the Lab," 2013). Experimental analysis of behavior must be a key component of 
that training. However, an exclusive focus on this area will not be enough. For example, 
imagine a self-administration study that combines testing the effectiveness of a potential 
medication to prevent reinstatement with a proteomic approach to begin identifying potential 
neural mechanisms of the drug’s action. The very nature of this hypothetical study (i.e., very 
large data set from the gene assay), combined with the desire to ensure the continued 
reproducibility and reliability of our work, prompts the need to use statistical procedures that 
appropriately account for errors in hypothesis testing. Further, leveraging recent advances 
and up-to-date statistical methods such as multilevel regression modeling and robust 
estimation will keep the field on the cutting-edge and aid in achieving our goals.
Greater emphasis needs to be placed on the detailed reporting of methodological practices. 
Publications in some of our most highly-regarded periodicals are often severely lacking in 
detail, making the results difficult to evaluate or reproduce. There is enough blame to go 
around. The journals put significant restrictions on manuscript length and word count, thus 
forcing authors to make compromises to meet those requirements. In an era of online 
publishing, DOIs, and PDFs, this practice seems antiquated and makes little sense. Of 
course, investigators could make better use of supplemental section when available in a 
journal. Additionally, we should take care to write the methods section from the perspective 
of someone in a different laboratory that wants to replicate and extend the study. Sometimes 
small details that are routine in a laboratory, and could be easily overlooked, may matter for 
replication. For example, a small detail in our intravenous drug self-administration protocol 
is that we start each session with a priming infusion that fills the internal volume of the 
indwelling jugular catheter (Charntikov et al., 2015). This step has the effect of more closely 
equating the volume of drug delivered into the vein on the first earned infusion with the 
volume of later infusions. Not only do we believe it is good scientific practice to control 
such factors when possible, we also believe that it matters and may affect behavioral or 
neuropharmacological outcomes.
Better communication
One of the major recurring themes of our discussions for this commentary was the critical 
need for behavioral pharmacologists to openly engage in scientific communication at 
multiple levels. The NIH budget has stagnated over the past decade. Not only has funding 
not adjusted for inflation ($28.1 billion in 2004 to $30.1 billion in 2014), but it has actually 
decreased in real dollars ($31 billion in 2010) over the past five years (NIH, 2015). It is 
imperative that we communicate with our congressional delegations the benefits of a well-
funded scientific community and highlight the importance of basic scientific research to the 
long-term health and well-being of society, as well as the economic impact of these 
advances. Notably, some allied professional societies (e.g., American Psychological 
Association [APA], American Society for Pharmacology and Experimental Therapeutics 
[ASPET], Society for Neuroscience [SfN]), provide fellowships and/or workshops that 
inform scientists on best practices for more effectively communicating with legislators.
As behavioral pharmacologists, we will also need to actively convey the importance of our 
field to scientific colleagues in other disciplines when given the opportunity. A deeper 
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appreciation of behavioral pharmacology may serve us well when these colleagues are 
serving on Center for Scientific Review (CSR) Study Sections for NIH. Finally, scientific 
communication with our local community is a necessity. The measles outbreak in December 
2014 – January 2015 sourced to Disney theme parks in Orange County, California, and 
spread largely by unvaccinated individuals, provides an alarming example of how scientific 
repudiation is a grave public health concern (Zipprich et al., 2015). Community outreach in 
the form of public forums, guest teaching in our local science classrooms, as well as 
informal discussions with our friends and family will help educate the public on the 
scientific process and instill trust in science and its outcomes. The Society for Neuroscience 
has Brain Awareness Week and, as an example, provides many supports for how to engage 
children and teachers in public schools about the benefits of neuroscience research. Perhaps 
we can steal a page from their playbook and encourage the leaders of our scientific 
organizations (e.g., Division 28 [Psychopharmacology and Substance Abuse] of the APA or 
the Behavioral Pharmacology Society) to coordinate such efforts. Interaction with members 
of our community may also come in the form of outreach through social media. Behavioral 
pharmacologists publishing books targeted at non-scientist may also increase accessibility 
and appreciation of our field. A well-informed public may even aid in the expansion of 
government funded scientific research. The bottom line here is that communication at all 
levels, local to federal, is paramount to the success of the field of behavioral pharmacology, 
and science in general.
Closing Reflections
I (Bevins) recommend that every laboratory PI prompt this conversation every so often. We 
frequently have informal conversations about the current status and the future of behavioral 
pharmacology, but there is something different about formalizing the discussion. It was 
illuminating to hear what topics and concerns were on the minds of my trainees. The 
positive framing for solutions was constructive. Perhaps some of the issues were predictable 
and stand the test of time (e.g., availability of jobs). However, each trainee differs and the 
potential constructive solutions or actions for that future behavioral pharmacologist may 
differ from past trainees. Regardless, these types of conversations can inform mentoring and 
recommendations for training in an ever evolving field. Finally, thanks to Dr. Poling for 
prompting these conversations; they were eye opening.
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